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N-Acetylprocainamide (NAPA), a class III antiar-
rhythmic drug, caused torsade de pointes in a 72 year
old woman who had this arrhythmia on two previous
occasions while being treated with quinidine and diso-
pyramide. Initial evaluation with an intravenous infu-
sion of NAPA indicated a favorable antiarrhythmic reo
Torsade de pointes has been described as a complication of
therapy with an increasing number of antiarrhythmic drugs
and dramatically illustrates the potential of these agents to
induce life-threatening ventricular arrhythmias (1-3). N-
AcetyIprocainamide (NAPA) is an active metabolite of pro-
cainamide, which was previously implicated as a cause of
torsade de pointes in a patient who was being treated with
procainamide and had a plasma procainamide level of 4.1
JLg/ml (within the generally accepted therapeutic range) and
a NAPA level of 32.8 JLg/ml (4). We report on the first
patient who developed this arrhythmia while receiving NAPA
and demonstrate the potential of this drug to cause torsade
de pointes.
Case Report
Because procainamide-induced lupus erythematosus may
remit during NAPA therapy (5), a 72 year old woman with
recurrent ventricular tachycardia and procainamide-induced
lupus was hospitalized to evaluate her response to NAPA.
She had a history of type II diabetes mellitus, angina pectoris
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sponse. The QTc interval was prolonged, but the 2.4
msIJLgper ml incrementalQTc interval lengtheningcaused
by NAPA was not greater than usual. During subsequent
oral therapy with NAPA, torsade de pointes developed
at plasma levels of this drug that appeared to be well
tolerated during the initial evaluation.
and two myocardial infarctions within the past 5 years. She
had recurrent polymorphic ventricular tachycardia and had
been resuscitated three times while receiving either quini-
dine or disopyramide therapy. The first resuscitation did not
occur while the patient was hospitalized. However, torsade
de pointes was documented on the latter two occasions and
was attributed to quinidine the first time and disopyramide
the second. Just before these episodes, the QTc interval of
normal sinus rhythm and postextrasystolic beats averaged
0.56 and 0.61 second, respectively, when the patient was
receiving quinidine, and 0.58 and 0.69 second, respectively,
when the patient was receiving disopyramide. For 3 months
before admission, she had been treated with procainamide
(Procan SR), 500 mg every 6 hours, but had developed
disabling stiffness and arthralgias in the joints of the hands,
wrists, hips and knees. These symptoms were partially con-
trolled with prednisone, 10 mg every other day. The patient
was also being treated with digoxin, 0.25 mg/day, pro-
pranolol, 10 mg every 6 hours, insulin, furosemide, potas-
sium chloride, aspirin and topical nitroglycerin.
Admission physicalfindings included a pulse rate of 80/min
with frequent extrasystoles, a blood pressure of 160/80 mm
Hg, a grade 2/6 systolic ejection murmur and an S4 gallop
rhythm. There was a minimal pretibial edema and peripheral
pulses were decreased in both legs. Range of motion was
decreased in the wrists, hands, hips and knees. The elec-
trocardiogram showed frequent ventricular premature com-
plexes, a QTc interval of 0.45 second (normal 0.35 to 0.44)
and left ventricular hypertrophy. Serum electrolytes were
within normal limits. The antinuclear antibody titer was
0735-1097/84/$3.00
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positive at a I: 10,240 dilution . Trough procainamide and
NAPA plasma levels were 1.7 and 5.8 JLg/ml , respectively.
The trough plasma digoxin level was 1.3 ng/ml and the
propranolol level was 9.0 ng/ml.
Methods
The research protocol for this investigation was approved
by the Northwestern University Institutional Review Board
on December 17, 1982. Informed consent was obtained
using forms that were reviewed as a part of this protocol.
NAPA formulations and assay. The hydrochloride salt
of NAPA was administered in a 100 mg/ml aqueous par-
enteral solution and as 500 mg tablets (American Critical
Care). Plasma concentrations of procainamide and NAPA
were measured by high performance liquid chromatography
(6).
Electrocardiographic monitoring. The patient under-
went on-line electrocardiographic monitoring during the en-
tire study . The electrocardiogram was displayed on an os-
cilloscope, recorded on tape and simultaneously analyzed
by a General Automation SPC-16/40 computer that was
programmed to count the frequency of ventricular premature
complexes during consecutive time intervals . After initial
manual adjustment of recognition variables for each patient,
this computer has been found to have a diagnostic accuracy
of 94.4% with a 4.3% mean rate of false positive ventricular
premature beat identification and a 2.3% mean rate of false
negative identification (7). Episodes of ventricular tachy-
cardia and torsade de pointes were identified by retrospective
review of the electrocardiographic tape recording. QT in-
tervals were measured manually from electrocardiographic
tracings transcribed from the tapes at a paper speed of 25
mm/s. QT intervals were measured in 10 cycles and were
averaged after applying the Bazett formula to correct for
changes in heart rate (8).
Short-term antiarrhythmic testing and kinetic anal-
ysis. The patient's initial response to NAPA therapy was
evaluated by a modification of a short-term testing procedure
that has been developed for determining antiarrhythmic drug
efficacy (9). A Sage pump was used to administer an initial
30 minute intravenous placebo infusion that was followed
30 minutes later by the infusion of 1.5 g of NAPA hydro-
chloride over a period of 30 minutes. Plasma NAPA con-
centrations produced by this intravenou s infusion were ana-
lyzed with the SAAM 23 digital computer program developed
by Berman and Weiss (10) and implemented on a Control
Data Corporation Cyber 1701730 computer. The disposition
kinetics of NAPA were modeled with a three compartment,
open mammillary system with elimination from the central
compartment. The relation between estimated biophase con-
centrations of NAPA and QTc interval prolongation was
analyzed with a linear effect model, similar to that previ-
ously used to study the vasodilator- and ganglionic-blocking
actions of this drug (II) . The results of this analysis and
NAPA plasma concentrations measured during subsequent
therapy with the oral formulation of this drug were then
used to calculate expected QTc intervals that could then be
compared with the actual values. An EM A x model was used
to analyze the relation between ventricular premature beat
frequency and NAPA concentrations in this biophase com-
partment (12).
Results
Initial evaluation. Four episodes of nonsustained ven-
tricular tachycardia « 10 consecutive beats) were observed
during the first 8 hours after admission, and ventricular
premature beat frequency averaged 5.4/min. Procainamide
was then discontinued and the patient was observed without
receiving antiarrhythmic therapy for the next 18 hours. Dur-
ing this time, plasma procainamide and NAPA levels de-
creased to 0.4 and 3.4 JLg/ml, respectively, and the patient
had 14 episodes of nonsustained multiform ventricular
tachycardia at a rate as high as 140 beats/min . Ventricular
premature beat frequency averaged 6.4/min during the last
8 hours of this period .
Response to intravenous NAPA infusion. The intra-
venous infusion produced peak plasma NAPA levels of 36.3
JLg/ml and was accompanied by the changes in ectopic beat
frequency and QTc intervals shown in Figure 1. There were
three episodes of three to four beat ventricular tachycardia
(maximal rate = 182 beats/min) during the first 15 minutes
after the intravenous infusion was completed, but then none
occurred for 13 hours. The infusion was well tolerated,
although mean arterial pressure decreased from 93 mm Hg
during the placebo period to a minimum of 73 mm Hg 5
minutes after the infusion was completed. Pharmacokinetic
analysis indicated that the elimination half-life and clearance
of NAPA were 8.1 hours and 139.6 ml/min, respectively,
and that the steady state distribution volume was 106 liters
or 1.2 liters/kg. Analysis of drug-induced prolongation of
QTc interval indicated that this interval was prolonged by
2.4 ms for every I JLg/ml increment in biophase NAPA
concentration. The rate constants for NAPA entry and exit
from the hypothetical biophase compartment were 0.020
and 0.161 min -I, respectively, so that maximal QTc in-
terval prolongation would be expected 14.7 minutes after
bolus intravenous injection. Intrinsic variability in the fre-
quency of ventricular premature beats precluded rigorous
correlation of changes in ectopic beat frequency with NAPA
plasma levels during the entire study period. However, anal-
ysis of observations made during the placebo period and the
first 4 hours after NAPA infusion suggested that this drug
suppressed ventricular premature beats in a dose-dependent
manner and that a NAPA plasma concentration of 8.5 JLg/ml
would effect half maximal suppression.
Because of this favorable response to short-term antiar-
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Figure2. Modified electrocardiogram of lead V1 obtained several
seconds before (A) andduring (B) the episode of NAPA-induced
torsade de pointes that required cardioversion. The normal sinus
beats inAhave a QTc interval of0.53 second (QT = 0.48 second).
The sequence leading to this arrhythmia (B) began when a pre-
mature ventricular beat (arrow 1) was followed by a long com-
pensatory pause that was ended by a supraventricular beat (arrow
2) that had a QTc interval of 0.60 second (QT = 0.54 second).
The subsequent ventricular premature beat (arrow 3) had a cou-
pling interval of 0.62 second andinitiated ventricular tachycardia.
later, the patient developed torsade de pointes (Fig. 2) that
degenerated into ventricular fibrillation requiring direct cur-
rent cardioversion and lidocaine therapy. At this time, the
plasma NAPA level was 32.4 j.tg/ml. The expected QTc
interval of 0.49 second agreed closely with the value of
0.50 secondmeasured during intervals of normal sinus rhythm
15 minutes before this episode. However, the QTc interval
of the normal beats and the postextrasystolic beat that im-
mediately preceded the torsade de pointes were 0.53 and
0.60 second, respectively. Serum potassium, calcium and
magnesium concentrations were 4.3 mEq/liter, 7.6 mg/dl
and 2.2 mg/dl, respectively.
Follow-up, The patientwas subsequently withdrawn from
lidocaine therapy and consented to invasive studies that she
had previously refused. Ventricular tachycardia could not
be induced by programmed electrical stimulation with ven-
tricular burst pacing and SJ, Sz and S3 stimuli at multiple
cycle lengths applied to right ventricular apical and outflow
sites. A gated pool scan demonstrated a large dyskinetic
area and a possible apical aneurysm in the left ventricle.
Although the patient continued to have frequent ventricular
premature beats and spontaneous episodes of nonsustained
ventricular tachycardia, the QTc interval of normal beats
was 0.43 second and that of postextrasystolic beats was
0.47 second; she was discharged from the hospital without
further antiarrhythmic therapy. For 5 months since dis-
charge, she has not had symptomatic ventricular tachycardia.
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Figure I. Initial evaluation of the patient's response to NAPA.
Halfan hour after a 30 minute placebo infusion (P), NAPA was
infused intravenously over 30 minutes. Plasma NAPA concentra-
tions (bottompanel) were used for kinetic analysis of concentra-
tion-related changes inQTc interval (middle panel)and ventricular
premature beat frequency (VPBs/min) (top panel). The QTc in-
terval averaged 0.43 second during theplacebo period and reached
a maximal value of 0.50 second shortly after the NAPA infusion
was stopped; respective values of QT were 0.38 and 0.45 second.
4
[NAP~ 10
Jlg/ml 8
6
rhythmic testing, the patient was started on oral therapy
with a NAPA dose of 1.5 g every 8 hours, which was
expected to provide mean plasma NAPA concentrations of
approximately 20 j.tg/ml. Ectopic ventricularpremature beat
frequency averaged 4.4/min during the first two dosing in-
tervals. Evaluation at that time indicated the return of ep-
isodic nonsustained ventricular tachycardia with a maximal
rate of 205 beats/min. The trough NAPA level was 14.0
j.tg/ml and the QTc of 0.45 second was close to the value
of 0.46 second estimated from the kinetic analysis.
Development of torsade de pointes. We attempted to
suppress the nonsustained ventricular tachycardia by in-
creasing the NAPA dose to 2.0 g every 8 hours. Three hours
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References
Torsade de pointes most commonly results from drug
therapy, and class I antiarrhythmic agents have been im-
plicated most frequently (1-3). Recent reports indicate that
this arrhythmia can be caused by amiodarone, a class III
antiarrhythmic drug (13). N-Acetylprocainamide, NAPA,
belongs to this antiarrhythmic class, because its primary
electrophysiologic action is to prolong action potential du-
ration (14).
Characteristics of this episode of torsade de pointes.
Torsade de pointes is thought to be a reentrant arrhythmia
that arises from inhomogeneous repolarization of neigh-
boring areas of myocardium (15). The QT interval is pro-
longed, usually exceeding 0.60 second immediately before
the onset of this arrhythmia (2,3), and the arrhythmia is
initiated by a ventricular premature beat with a coupling
interval ranging from 0.44 to 0.68 second (3). It has recently
been shown (16) that the ventricular beats immediately pre-
ceding the onset of torsade de pointes exhibit a long-short
cycle sequence. The episode of torsade de pointes shown
in Figure 2 exhibits these features, as well as the changing
ventricular complex configuration that is characteristic of
this arrhythmia.
Fallibility of short-term antiarrhythmic testing.
Potential aggravation of ventricular arrhythmias by antiar-
rhythmic drugs constitutes a major rationale for systematic
initial drug testing before beginning long-term antiar-
rhythmic therapy (17). However, our patient demonstrated
an apparently favorable response to an initial intravenous
infusion of NAPA that encompassed plasma levels that later
caused torsade de pointes. During this evaluation, QT in-
tervals were prolonged. This prolongation primarily re-
flected the patient's relatively long baseline QT interval,
because the incremental prolongation associated with NAPA
therapy was no greater than that reported in patients (18)
who subsequently tolerated long-term therapy with NAPA
levels as high as 30 to 50 j.Lg/ml (19). Hypokalemia and
hypomagnesemia are commonly present when patients de-
velop torsade de pointes despite normal plasma levels of
antiarrhythmic drugs (16), but were excluded as contribu-
tory factors in our patient. Although we cannot explain why
torsade de pointes subsequently developed at NAPA plasma
levels that initially appeared to be well tolerated, it is clear
that response to short-term antiarrhythmic drug testing may
not always predict subsequent therapeutic outcome.
The NAPA for these investigations was kindly supplied by Douglas Allin
of American Critical Care.
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